Context: US Tariff Patented Pharma
The US has imposed a 100% tariff on patented pharmaceutical imports (from July 31) to promote domestic manufacturing and reduce supply dependence; generic drugs are exempt for now, with a review after 12 months.
Key Points
- What is being taxed (Basics included)
• Patented drugs → new, innovation-based medicines under patent protection (~20 years), high-cost, no competition
• Generics → copies made after patent expiry, low-cost, mass supply
• Tariff applies to patented drugs and related inputs, generics excluded currently - Why US is doing this
• Reduce import dependence in a critical sector
• Boost domestic pharma manufacturing
• Secure supply chains
• Strategic push similar to semiconductors/critical tech - India–US Pharma Link (Data)
• US = largest market (~40% of India’s pharma exports)
• India exports ~$9.7 billion (2025)
• ~90% exports are generics → shielded for now - Impact on India
• Short term → limited impact (generics exempt)
• Direct impact → firms in patented/specialty segment face pressure
• Risk → if tariffs extend to generics → major export shock
Structural Implications
• Push for US-based manufacturing
• Possible decline in reliance on Indian APIs/intermediates
• Opportunity for India to move into high-value pharma (PLI ~₹15,000 crore)
